Trials / Recruiting
RecruitingNCT07195604
A Single Ascending Dose of HRS-2162 in Healthy Subjects
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of a Single Dose of HRS-2162 Injection in Healthy Subjects
- Status
- Recruiting
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 64 (estimated)
- Sponsor
- Fujian Shengdi Pharmaceutical Co., Ltd. · Industry
- Sex
- All
- Age
- 18 Years – 45 Years
- Healthy volunteers
- Accepted
Summary
The study is being conducted to evaluate the safety and tolerability of HRS-2162 injection in a single dose in healthy subjects, as well as the characteristics of PK/PD
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | HRS-2162 | HRS-2162 |
| DRUG | Placebo | Placebo |
Timeline
- Start date
- 2025-09-25
- Primary completion
- 2025-12-01
- Completion
- 2025-12-01
- First posted
- 2025-09-26
- Last updated
- 2025-11-17
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT07195604. Inclusion in this directory is not an endorsement.